Responses
Clinical and epidemiological research
Extended report
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Compose a Response to This Article
Other responses
No responses have been published for this article.